Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 24, 2017
What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?
TEVA has seven hundred and seven approved drugs.| International Patents: | 890 |
| US Patents: | 72 |
| Tradenames: | 467 |
| Ingredients: | 409 |
| NDAs: | 707 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
omacetaxine mepesuccinate | for Injection | 3.5 mg/vial | SYNRIBO | 10/26/2016 |
omeprazole | Delayed-release Tablets | 20 mg | OMEPRAZOLE | 6/3/2015 |
glatiramer acetate | Injection | 40 mg/mL, 1 mL pre-filled syringe | COPAXONE | 2/26/2014 |
glatiramer acetate | Injection | 40 mg/mL, 1 mL pre-filled syringe | COPAXONE | 1/29/2014 |
levonorgestrel; ethinyl estradiol;ethinyl estradiol | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | QUARTETTE | 7/10/2013 |
rasagiline mesylate | Tablets | 0.5 mg and 1 mg | AZILECT | 5/17/2010 |
dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfa | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ADDERALL 30 | 11/18/2009 |
levonorgestrel;ethinyl estradiol;ethinyl estradiol | Tablets | 0.1 mg/0.02 mg and 0.01 mg | LOSEASONIQUE | 11/16/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.3 mg, 0.45 mg and 0.9 mg | CENESTIN | 3/19/2009 |
conjugated estrogen (synthetic a) | Tablets | 0.625 mg | CENESTIN | 3/2/2009 |
conjugated estrogen (synthetic a) | Tablets | 1.25 mg | CENESTIN | 11/3/2008 |
cyclobenzaprine hydrochloride | Extended-release Capsule | 15 mg and 30 mg | AMRIX | 8/11/2008 |
levonorgestrel; ethinyl estradiol; ethinyl estradiol | Tablets | 0.15 mg/0.03 mg/0.01 mg | SEASONIQUE | 1/22/2008 |
levonorgestrel and ethinyl estradiol | Tablets | 0.15 mg/0.03 mg | SEASONALE | 3/29/2004 |
| Patent Number | Expiration Date |
|---|---|
| ► Subscribe | ► Subscribe |
| ► Subscribe | ► Subscribe |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,227,454 | Estrogenic compounds, pharmaceutical compositions and formulations comprising the same | ► Subscribe | |||||||||||||
| 7,619,117 | Rasagiline formulations and processes for their preparation | ► Subscribe | |||||||||||||
| 9,533,111 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||
| 7,459,445 | Estrogenic compounds and topical pharmaceutical formulations of the same | ► Subscribe | |||||||||||||
| 7,842,687 | Cephalotaxane derivatives and their processes of preparation and purification | ► Subscribe | |||||||||||||
| 6,743,413 | Suspension aerosol formulations | ► Subscribe | |||||||||||||
| 5,387,612 | Use of the R-enantiomers of N-propargyl-1-aminoindan compounds for treating Parkinson's disease | ► Subscribe | |||||||||||||
| 9,737,674 | Dose counters for inhalers, inhalers and methods of assembly thereof | ► Subscribe | |||||||||||||
| 8,338,396 | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | ► Subscribe | |||||||||||||
| 7,169,774 | Cephalotaxane derivatives and their processes of preparation and purification | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2935569 | ► Subscribe | |||||||||||||
| Hong Kong | 1222127 | ► Subscribe | |||||||||||||
| Japan | 2005516913 | ► Subscribe | |||||||||||||
| Hungary | E032058 | ► Subscribe | |||||||||||||
| Slovakia | 501352015 | ► Subscribe | |||||||||||||
| New Zealand | 603466 | ► Subscribe | |||||||||||||
| Spain | 2544437 | ► Subscribe | |||||||||||||
| Hong Kong | 1222150 | ► Subscribe | |||||||||||||
| Cyprus | 1114421 | ► Subscribe | |||||||||||||
| Australia | 2008237614 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00C/001 | Belgium | ► Subscribe | PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306 | ||||||||||||
| C0022 | France | ► Subscribe | PRODUCT NAME: MONTELUKAST SODIUM; REGISTRATION NO/DATE IN FRANCE: NL 23 133 DU 19980320; REGISTRATION NO/DATE AT EEC: 13 651 DU 19970825 | ||||||||||||
| C0030 | France | ► Subscribe | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 | ||||||||||||
| 2014 00034 | Denmark | ► Subscribe | PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220 | ||||||||||||
| 2016000120 | Germany | ► Subscribe | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713 | ||||||||||||
| 90020-1 | Sweden | ► Subscribe | PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123 | ||||||||||||
| 2015 00017 | Denmark | ► Subscribe | PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720 | ||||||||||||
| 02C/035 | Belgium | ► Subscribe | PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517 | ||||||||||||
| /2000 | Austria | ► Subscribe | PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201 | ||||||||||||
| C/GB98/017 | United Kingdom | ► Subscribe | PRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 23,019 others who get our Drug Patent Expiration Alerts:
